ClinicalTrials.gg
RecruitingNCT07136506ActiControlUpdated May 19, 2026

Gait Analysis Parameter and Upper Limb Evaluation in Control Participants

An interventional study of Syde and Post-recording questionnaire in Healthy Participants, sponsored by Centre Hospitalier Universitaire de Liege. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Centre Hospitalier Universitaire de Liege · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The ActiControl study is a monocentric, academic, and fully remote observational study designed to build a normative, longitudinal dataset using the Syde® wearable device. The study will enroll 200 healthy volunteers across all age groups, genders, and backgrounds. Participants will be remotely recruited and followed over two years, wearing the Syde® device for 3-week periods every 6 months. All study visits, including consent, data collection, and follow-up, are conducted remotely via phone or video conferencing. The primary objectives are to collect reference data on gait and movement patterns and to assess adherence and acceptability of the device. Secondary objectives include evaluating the reliability of digital endpoints and the influence of demographic and lifestyle factors on these measures.

Read the detailed description

Rare diseases, though individually uncommon, collectively affect approximately 5% of the European population, with many presenting neurological symptoms and significant societal burden. Clinical trials in this field face challenges such as small sample sizes and subjective outcome measures. To address these limitations, wearable technologies like Syde® and ActiMyo® have been developed to objectively quantify motor function using inertial sensors.

The Syde® device, worn on the wrist and ankle(s), continuously records upper- and lower-limb movements. One of its key metrics, the 95th percentile of stride velocity (SV95C), has been endorsed by the European Medicines Agency as a valid primary outcome in Duchenne Muscular Dystrophy (DMD) trials. Syde® has also been used in studies involving Spinal Muscular Atrophy (SMA), Angelman Syndrome, Facioscapulohumeral Muscular Dystrophy (FSHD), and other neurological conditions, as well as in healthy controls under 20 years old.

To further validate digital outcome measures, normative data across all age groups is essential. The ActiControl study will enroll 200 healthy volunteers (approximately 20 per decade from ages 0 to 90), ensuring balanced representation by gender, ethnicity, and socioeconomic status.

All study procedures are conducted remotely. Participants are recruited and enrolled electronically, including remote signing of the informed consent form. Demographic and health data (e.g., age, sex, height, weight) are collected via phone or video call at inclusion and every 6 months for 2 years. Participants will wear the Syde® device for 3 weeks at five timepoints (baseline, 6, 12, 18, and 24 months).

Primary objectives include:

Building a longitudinal dataset of Syde® digital variables. Assessing adherence and acceptability of the device across age groups.

Secondary objectives include:

Evaluating the reliability of Syde®-derived variables. Investigating the influence of demographic and lifestyle factors (e.g., age, gender, BMI, physical activity, seasonality) on digital endpoints.

Outcome measures include stride velocity, stride length, walking time, step asymmetry, stair climbing metrics, and more.

This study will contribute to the establishment of robust normative data, enabling more accurate interpretation of digital biomarkers in future clinical trials for rare and neurological diseases.

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy Participants
  • Healthy Volunteers
  • Healthy Adults
03

In context

Lead sponsor

Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female of different age groups
  • Signed form by participant him/herself or, in case of patients \<18 years old, signed informed consent form by patient's parents or legal guardians
  • Able to ambulate (minimum 10 meters without help)
  • Participant willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs
  • Elite athletes (at the national level)
  • Pregnant women
  • A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion
  • An orthopedic, neuromuscular, or neurological pathology that affects the quality of the participant's walking gait
  • No access to unlimited internet connection or alternatively no capacity to come on-site to upload Syde data
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Control

    Device: Syde · Other: Post-recording questionnaire

Interventions

  • DeviceSyde

    Syde is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.

  • OtherPost-recording questionnaire

    The post-recording questionnaire aims at describing as much as possible the subject activity and quality of life during the recording period while being as low a burden as possible for the subject. The question formats are, on one hand, inspired by Quality of life and Physical Activity questionnaires usually used in Clinical Research and, on the other hand, based on device-specific needs for an optimal analysis. It covers fatigue status, physical status, physical activity with the Syde®, event(s) or condition(s) that may have impacted the ability to wear the Syde® during the recording.

06

What researchers measure

Primary outcomes

  1. Digital Mobility Monitoring Compliance

    Measure of participant adherence to wearing the Syde® device using different parameters including total recording time, number of valid recording days (≥4 hours), and time to reach 50 and 180 hours of recording.

    Time frame: 5 recording periods of 3 weeks over 2 years

  2. Walking Pattern Characteristics

    Analysis of walking sequences, including maximal walking sequence duration, maximal distance walked in a single sequence, and maximal 30-minute walking distance.

    Time frame: 5 recording periods of 3 weeks over 2 years

Secondary outcomes

  1. Device Acceptability and Adherence

    Measures of user engagement with the Syde® device across age groups and over time, including total recording time, valid days (≥5 hours), and time to reach 50 and 180 hours.

    Time frame: 5 recording periods of 3 weeks over 2 years

  2. Reliability of Digital Variables

    Test-retest reliability of Syde® digital variables assessed using intraclass correlation coefficients (ICC) between two consecutive half-periods.

    Time frame: 5 recording periods of 3 weeks over 2 years

  3. Association with Demographic and Health Factors

    Correlation of digital mobility outcomes with age, height, weight, BMI, and other demographic or health-related variables.

    Time frame: Over 2 years

  4. Group Differences in Digital Variables

    Comparison of digital mobility metrics across subgroups defined by gender, age, health status, education, socio-professional category, physical activity level, living environment, and seasonality.

    Time frame: Over 2 years

07

Study locations

1 of 1 sites recruiting
  • Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle
    Liège, 4000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 22, 2025
StartActual
Sep 24, 2025
Primary completionEst.
Sep 2028
CompletionEst.
Dec 2028
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136506
Lead sponsor
Centre Hospitalier Universitaire de Liege
Collaborators
Centre Hospitalier Régional de la Citadelle, SYSNAV
Responsible party
Laurent Servais (Principal Investigator, Pediatrician, Centre Hospitalier Universitaire de Liege) — Principal investigator
First posted
Aug 22, 2025
Start date
Sep 24, 2025
Primary completion
Sep 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 19, 2026

Study contacts

Nicolas Bovy
Contact
Nicolas.Bovy@citadelle.be
+3243218095
Laurent Servais, MD
principal investigator · Centre Hospitalier Universitaire de Liege

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion